3.33
+4.06%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Theranexus
Its shares trade on Euronext Paris under the ticker ALTHX.PA. It has been listed since 30 October 2017. In the fiscal year to 31 December 2024, it reported revenue of €2.3m and a net loss of €1.8m. At that date it held total assets of €3.7m and shareholders' equity of −€1.7m.
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Oct 2017
- Employees
- 16
- Website
- theranexus.com ↗
Leadership
Pay as last reported
- Mr. Mathieu CharveriatExecutive Chairman of the Board, Chief Executive Officer, since 2024€208,804
- Ms. Christine PlacetAdministrative and Financial Director
- Mr. Julien VeysChief Business Development Officer, Director, since 2016€145,499
- Ms. Marie SebilleMedical Director
- Mr. Franck MouthonNon-Executive Director, since 2017€67,524
- Mr. Rodolphe BesserveIndependent Director€7,500
- Mr. Jerome MartinezIndependent Director€7,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Theranexus SA excels in its commitment to innovative research and development, continuously striving to discover novel therapeutic solutions for various diseases.
- The company possesses a robust portfolio of intellectual property rights, providing a competitive advantage and ensuring protection of its innovative discoveries.
- Theranexus SA benefits from a skilled and diverse team of professionals, comprising scientists, researchers, and industry experts, who contribute to the company's success through their expertise and collaboration.
Weaknesses
- The company heavily relies on external funding sources for its research and development activities, which exposes it to potential financial uncertainties and limitations.
- Theranexus SA currently has a limited presence in the market, making it challenging to establish brand recognition and gain significant market share compared to more established competitors.
Opportunities
- As the demand for innovative therapies and personalized medicine increases, Theranexus SA has an opportunity to capitalize on this market trend by leveraging its research and development capabilities.
- Collaborating with renowned pharmaceutical companies or research institutions can enable Theranexus SA to leverage their resources, expertise, and distribution channels, accelerating the commercialization of their products.
Threats
- The biotechnology and pharmaceutical industry is highly competitive, with numerous players striving to develop breakthrough treatments. Theranexus SA faces the risk of competition from both established companies and emerging startups.
- Compliance with ever-changing regulations and obtaining necessary approvals from regulatory authorities pose challenges and can potentially delay the launch of Theranexus SA's products, impacting its market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.